Skip to main content

Table 2 Results of analysis of PSA-PFS by log-rank test

From: Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

   No. of patients No. of PSA progression 5 year PSA-PFS rate log-Rank
Total   649 161 71.2 %  
Age ≤75 265 66 73.9 %  
76≤ 384 95 69.0 % 0.230
T classification T1c 189 42 71.8 %  
T2ab 205 37 78.9 %  
T2c 104 36 65.2 % *
T3a 103 28 70.1 %  
T3b 48 18 54.0 %  
Stage B 498 115 73.2 %  
C 151 46 64.9 % 0.155
PSA level at diagnosis <10 197 31 83.2 %  
10-20 195 42 75.2 % **
20≤ 257 88 59.4 %  
Gleason score 6 288 60 76.2 %  
7 196 43 72.0 % ***
8≤ 165 58 61.8 %  
Laterality of cancer detected by biopsy Unilateral 365 66 77.2 %  
Bilateral 284 95 63.8 % <0.001
SVI Negative 601 143 72.7 %  
Positive 48 18 54.0 % 0.030
  1. PSA-PFS: PSA progression-free survival
  2. SVI: seminal vesicle involvement
  3. *: T1c vs. T2c; p = 0.036. T1c vs. T3b; p = 0.028. T2ab vs. T2c; p = 0.001. T2ab vs. T3b; p = 0.003. others; p > 0.05
  4. **: <10 vs. 10–20; p = 0.192. 10–20 vs. 20≤; p = 0.002. <10 vs. 20≤; p < 0.001
  5. ***: 6 vs. 7, p = 0.310. 7 vs. 8≤; p = 0.028. 6 vs. 8≤; p = 0.004